Comparing Once-Daily Versus Twice-Daily Ramipril Dosing for Kidney and Heart Function in Adults with Chronic Kidney Disease and Reduced Ejection Fraction Heart Failure

What this Trial Is About

Researchers are evaluating the effects of once-daily versus twice-daily dosing of ramipril on kidney function in patients who have chronic kidney disease CKD along with heart failure with reduced ejection fraction HFrEF. This study aims to understand how these dosing schedules influence important factors like plasma renin activity, inflammation markers, oxidative stress, and kidney health over a 30-day treatment period. It addresses the current uncertainty in treatment guidelines about the best dosing frequency for ramipril in these patients. Participants are randomly assigned to receive either 10 mg of ramipril once daily or 5 mg twice daily, both for 30 days. This is a double-blind study, meaning neither participants nor researchers know who receives which dosing schedule, to fairly compare the effects. The study focuses on measuring changes in biomarkers such as plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C to assess kidney function and related biological activity. During the study, patients will be monitored closely with laboratory tests to measure kidney function and inflammation at the start and after 30 days of treatment. Blood pressure and other safety indicators will also be checked. The main goal is to determine which dosing schedule better supports kidney health and reduces harmful biological changes in this patient group. The trial lasts 30 days, and participants health status and any side effects will be carefully observed throughout this period.

Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure